Targeting Ewing Sarcoma (ES), Osteosarcoma (OS) and Neuroblastoma (NB) with Anti-MCAM Chimeric Antigen Receptor (CAR) Modified Natural Killer (NK) Cells
Author Type(s)
Faculty
Document Type
Abstract
Publication Date
2022
Journal Title
Pediatric Blood and Cancer
Department
Pediatrics
Abstract
Background: Pediatric patients with metastatic ES, OS and NB have a dismal average 5-year survival (
Recommended Citation
Luo, W., Gardenswartz, A., Chu, Y., Rosenblum, J. M., Ayello, J., Marcondes, M., Overwijk, W. W., Cripe, T. P., Cassady, K. A., Lee, D. A., & Cairo, M. S. (2022). Targeting Ewing Sarcoma (ES), Osteosarcoma (OS) and Neuroblastoma (NB) with Anti-MCAM Chimeric Antigen Receptor (CAR) Modified Natural Killer (NK) Cells. Pediatric Blood and Cancer, 69 (Suppl. 2), S220-S221. https://doi.org/10.1002/pbc.29735
COinS
